Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2019-01-03
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial studies the side effects and best dose of ibrutinib when given together
with pembrolizumab and to see how well they work in treating patients with non-Hodgkin
lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as
pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Given pembrolizumab and ibrutinib may work better in treating patients with non-Hodgkin
lymphoma.